To the best of our knowledge, our study is the first to demonstrate the significance of the NUPR1/KDM3A/TFEB axis in TMZ resistance in glioma cells, and provides promising biomarkers for the treatment of glioma and a novel therapeutic approach to overcoming TMZ resistance. This evidence concerns the gene TFEB and central nervous system cancer.